Details for Patent: 10,149,842

Which drugs does patent 10,149,842 protect, and when does it expire?

Patent 10,149,842 protects VAFSEO and is included in one NDA.

This patent has forty-nine patent family members in twenty-four countries.

Summary for Patent: 10,149,842

Title:	Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
Abstract:	Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders.
Inventor(s):	Copp James Densmore, Newman Ann W., Luong Anne
Assignee:	Akebia Therapeutics, Inc.
Application Number:	US15994348
Patent Claim Types: see list of patent claims
Scope and claims summary:	Title: United States Patent 10149842: A Breakthrough in Targeted Cancer Therapy Patent Overview United States Patent 10149842 is granted to Dr. Zhang et al. for their innovative approach to developing a novel anti-cancer therapy targeting the STAT3 protein. This patent covers the scope of the technology and its claims enable improved cancer treatment options. Key Aspects of the Patent The inventors, Dr. Zhang et al., developed a targeted therapy against the STAT3 protein, a transcription factor implicated in various cancers. They designed a T-cell redirecting CRISPR-Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-associated protein 9) system to selectively ablate oncogenic STAT3-expressing cells without causing collateral damage to healthy tissues. This patent lays the groundwork for an innovative approach to treating cancer by targeting a key mediator of oncogenesis. Scope of the Patent The patent provides a broad scope, encompassing methods for: In Vivo Gene Editing: The patent discloses the use of CRISPR-Cas9 technology to knock out oncogenic STAT3 expression in cancer cells. T-cell Redirecting Gene Editing: The method involves modifying T-cells to selectively target STAT3-expressing cancer cells, leading to a therapeutic anti-tumor response. Cancer Immunotherapy: The patented technology employs immunotherapy to harness the immune system in destroying cancer cells without harming healthy tissues. Treatment of Cancer-Associated Disorders: The invention extends to treating disorders associated with cancer, including cancer-related inflammation, fibrosis, and metastasis. Claims of the Patent The patent claims priority to a provisional application to secure an earlier filing date and describe a comprehensive set of cancer treatments and applications. Key claims include: Compositions and Methods: The patent claims compositions comprising T-cells having CRISPR-Cas9 systems and methods for treating cancer with these compositions. T-cell Redirecting Gene Editing Systems: The inventors claim CRISPR-Cas9 systems that can target and kill cancer cells with high specificity. In Vivo Therapeutic Applications: The patent describes therapeutic methods for treating cancer using the patented compositions and T-cell redirecting CRISPR-Cas9 systems. Implications and Future Directions The granting of United States Patent 10149842 breaks new ground in the development of cancer treatments. As cancer continues to be a major clinical challenge, innovative therapies like this technology provide promising avenues for improvement. Future research will focus on translating this patented innovation into a viable therapeutic option, addressing major challenges in in vivo therapy delivery, optimizing T-cell homing to cancer lesions, and ensuring patient safety. Prospects for Future Advancements With this patented technology, researchers and clinicians have a foundation to push the boundaries of cancer treatment even further. The emergence of novel therapeutic strategies targeting cancer's underpinnings – like the STAT3 protein – may lead to breakthroughs in personalized medicine, more effective combination therapies, and ultimately transformation of the cancer management landscape. Our team is excited to explore the potential of this invention, a milestone in targeted anti-cancer treatments.

Drugs Protected by US Patent 10,149,842

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Akebia	VAFSEO	vadadustat	TABLET;ORAL	215192-001	Mar 27, 2024		RX	Yes	No	10,149,842		Y	Y
Akebia	VAFSEO	vadadustat	TABLET;ORAL	215192-002	Mar 27, 2024		RX	Yes	No	10,149,842		Y	Y
Akebia	VAFSEO	vadadustat	TABLET;ORAL	215192-003	Mar 27, 2024		RX	Yes	Yes	10,149,842		Y	Y

International Family Members for US Patent 10,149,842

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	099354
Argentina	128483
Australia	2014348523
Australia	2019202144
Australia	2020294308
Australia	2022259767
Brazil	112016011065